• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 rando...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Pamela J Goodwin Bingshu E Chen Karen A Gelmon Timothy J Whelan Marguerite Ennis Julie Lemieux Jennifer A Ligibel Dawn L Hershman Ingrid A Mayer Timothy J Hobday Judith M Bliss Priya Rastogi Manuela Rabaglio-Poretti Alastair M Thompson Daniel W Rea Paul M Source Type: research

The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Conclusion: According to the data of this meta-analysis, treatment with metformin failed to statistically improve liver enzymes but may be beneficial in the improvement of lipid parameters and insulin metabolism regulation in pediatric patients with NAFLD. As there are not enough available studies in the literature, the influence of metformin on liver ultrasonography or histology in pediatric NAFLD should be further analyzed in future studies.What is Known:• Lifestyle modification with weight loss through physical activity and dietary modification is the recommended treatment option for pediatric NAFLD.• Metformin may ...
Source: European Journal of Pediatrics - August 28, 2023 Category: Pediatrics Source Type: research

LEAP2 is Associated with Cardiometabolic Markers, but is Unchanged by Antidiabetic Treatment in People with Prediabetes
Conclusion FP-LEAP2 is associated with body mass, impaired insulin sensitivity, liver specific enzymes and kidney function. The findings highlight the importance of LEAP2 in obesity, type 2 diabetes, and non-alcoholic fatty liver disease. FP-LEAP2 was not affected by metformin, dapaglifloxin, or exercise in this population.PMID:37436962 | DOI:10.1152/ajpendo.00023.2023
Source: American Journal of Physiology. Endocrinology and Metabolism - July 12, 2023 Category: Physiology Authors: Sarah Byberg Martin B æk Blond Stephanie Holm Hanan Amadid Lea Bruhn Nielsen Kim Katrine Bjerring Clemmensen Kristine Faerch Birgitte Holst Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11